NEW YORK, July 3, 2014 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Regado Biosciences, Inc. ("Regado Biosciences" or the "Company") (NasdaqCM: RGDO). The investigation focuses on whether the Company and its executives violated federal securities laws.
On July 3, 2014 shares of Regado Biosciences fell $4.01 or 59.32% during intraday trading to trade at $2.75 after the company issued a press release on July 2, 2014, announcing, among other things, "that the Data Safety Monitoring Board, or DSMB, has initiated an unplanned review of data from the Company's Phase 3 trial of Revolixys Kit (previously known as REG1), entitled REGULATE-PCI, and that patient enrollment has been paused in the REGULATE-PCI trial until the DSMB has completed its analysis and communicated its recommendations."
If you are aware of any facts relating to this investigation, or purchased shares of Regado Biosciences, you can assist this investigation by contacting either Edward N. Gewirtz or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Edward N. Gewirtz or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC